



Khale Diagnostics, Inc

Khale Diagnostics is developing a revolutionary blood glucose monitor that has the potential of changing the way diabetics check their glucose levels. Rather than enduring the pain and inconvenience of drawing blood for routine testing, as all current consumer glucose tests require, diabetics will simply blow into the hand-held device and a few minutes later obtain a read-out of blood glucose level. Khale's breath-based technology which allows for point-of-need testing with quick and accurate results has the potential to open many new opportunities in the medical, home, law enforcement and industrial diagnostic markets. The company is developing a line of innovative breath-based devices to replace or supplement many conventional diagnostic tests.

Technology

Exhaled breath can be analyzed with a wide variety of commercially available sensors and biosensors. Researchers at the University of Florida have shown that numerous substances are detectable in breath and that the breath based results correlate closely with those of blood. Khale Diagnostics has licensed several patent applications and issued patents from the University of Florida and is developing a line of handheld or bench-top devices that will detect the presence and/or concentration of various substances in the blood using exhaled breath.

The use of exhaled breath as a diagnostic matrix offers many advantages over current blood and urine based techniques. One of the most valuable being that the measurement can be made at the point-of-need and the results obtained in real-time; there will no longer be a need to wait days for results as samples are shipped off to a lab for analysis. Tests of exhaled breath are non-invasive and completely hygienic for both the patient and the laboratory personnel. The sample from breath is also very pure, not requiring purification and isolation techniques often necessary with urine and blood.

Khale is developing breath-based diagnostic devices for the following markets:

- ◆ Glucose Monitoring – for diabetics to routinely monitor their blood glucose level.
- ◆ Therapeutic Drug Monitoring – for monitoring clinical trials and for patients taking certain medications that require routine blood monitoring,
- ◆ Drugs of Abuse Testing – for roadside testing by police, for hospital emergency rooms, and for workplace testing.

Market Potential

Diagnostic testing currently represents a \$28 billion worldwide market. Khale Diagnostics is developing a line of breath-based diagnostic devices expected to replace many current blood and urine tests by providing near-instantaneous real-time results.

Strategy

Khale's strategy is to collaborate with development partners, such as with airborne detector manufacturers and molecular marker developers to develop detection tools for illicit drug screening, and for drug and glucose monitoring. The technology is potentially applicable across broad range of market applications. Some of the markets the company plans to address in the future include: occupational exposure detectors, drug metabolism, and bio-defense / military applications.

Management Team

Chief Executive Officer – Richard R. Allen

Mr. Allen has 30 years of experience in business and finance, including 16 years in executive leadership positions with medical technology businesses. He co-founded Regeneration Technologies (Nasdaq: RTIX) a medical device company and founded Synogen, a private venture fund investing in early-stage biomedical and medical device companies. Mr. Allen is a licensed CPA in the state of Florida.

Vice President of Product Development and co-founder – Richard J. Melker M.D., Ph.D.

Dr. Melker is Professor of Anesthesiology, Pediatrics and Biomedical Engineering at the University of Florida and is the Director of the Florida Anesthesiology Computer and Engineering Team (FACET) which develops and licenses medical devices and technologies. He previously served as Director of Emergency Services at Shands Hospital, and as Medical Liaison for the NASA space shuttle program. Dr. Melker received his M.D. and Ph.D. in Neurobiology from Albert Einstein College of Medicine.

Vice President of Scientific Affairs and co-founder – Donn Dennis, M.D., F.A.H.A.

Dr. Dennis is a board certified Anesthesiologist and is a Professor in the College of Medicine at University of Florida in the departments of Anesthesiology, Psychiatry, and Pharmacology and Experimental Therapeutics. He is the Director of Nanomedicine at the University of Florida and holds the Joachim S. Gravenstein M.D. Endowed Chair in Anesthesiology. He previously served as Vice President of Pharmacology at ARYx Therapeutics. Dr. Dennis received his medical degree from the University of Michigan.

Vice President of Business Development – Stephanie Warrington, M.B.A, M.H.A

Ms. Warrington has experience in the health care industry with Humana and Blue Cross Blue Shield of Florida and in commercializing cutting-edge biomedical technologies with Synogen and with the Office of Technology and Licensing at the University of Florida. Ms. Warrington obtained her graduate degrees from the University of Florida College of Business.

Contact Information

Xhale Diagnostics, Inc.
101 SE 2nd Place- Suite 201A
Gainesville, FL 32601
Phone: (352) 371-2075
Email: info@xhalediagnostics.com
www.xhalediagnostics.com

Contact: Richard R. Allen, CEO
Email: rallen@xhalediagnostics.com

For more information about this UF start-up company or other spin-off opportunities from the University of Florida, contact our UF TechConnect Coordinator:

Chris Brown, EDA University Center Coordinator
cbrown11@rgp.ufl.edu
(352) 846-1840

September 2006